Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS

Cellular Immunology

Volumn 287, Issue 1, 2014, Pages 1-17

  Kong, Weimin ^a   Li, Hongbo ^a   Tuma, Ronald F ^a   Ganea, Doina ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabinoid receptor; Chemokines; EAE; Gp1a; Th17 differentiation

Indexed keywords

(PIPERIDIN 1 YL ) 1 (2,4 DICHLOROPHENYL) 1,4 DIHYDRO 6 METHYLINDENOL[1,2 C]PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 2 RECEPTOR AGONIST; CD3 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 23P19; INTERLEUKIN 4; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AXONAL LOSS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATION; EARLY INTERVENTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOLOGY; IMMUNOCOMPETENT CELL; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; MACROPHAGE; MICROGLIA; MICROVASCULATURE; MONONUCLEAR CELL; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TH1 CELL; TH17 CELL; TH2 CELL; THERAPY DELAY;

ANTIGEN-PRESENTING CELL; APC; BBB; BLOOD BRAIN BARRIER; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR 1; CANNABINOID RECEPTOR 2; CB1; CB2; CENTRAL NERVOUS SYSTEM; CHEMOKINES; CNS; DC; DENDRITIC CELL; EAE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FACS; FLUORESCENCE ACTIVATED CELL SORTER; GP1A; LIPOPOLYSACCHARIDE; LPS; MNCS; MOG; MONONUCLEAR CELLS; MS; MULTIPLE SCLEROSIS; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PBS; PERTUSSIS TOXIN; PHOSPHATE BUFFERED SALINE; PT; QRT-PCR; QUANTITATIVE RT-PCR; T CELL RECEPTOR; TCR; TH17 DIFFERENTIATION;

ANIMALS; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; CHEMOKINES; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INDENES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROIMMUNOMODULATION; PEPTIDE FRAGMENTS; PYRAZOLES; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CHEMOKINE; TH1 CELLS; TH17 CELLS;

EID: 84890159372     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.11.002     Document Type: Article

References (48)

1. Pacher P., Kunos G. Modulating the endocannabinoid system in human health and disease - successes and failures. FEBS J. 2013, 280:1918-1943.
2. Pacher P., Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system?. Prog. Lipid. Res. 2011, 50:193-211.
3. Saito V.M., Rezende R.M., Teixeira A.L. Cannabinoid modulation of neuroinflammatory disorders. Curr. Neuropharmacol. 2012, 10:159-166.
4. Sanchez A.J., Garcia-Merino A. Neuroprotective agents: cannabinoids. Clin. Immunol. 2012, 142:57-67.
5. Kubajewska I., Constantinescu C.S. Cannabinoids and experimental models of multiple sclerosis. Immunobiology 2010, 215:647-657.
6. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
7. Engelhardt B., Ransohoff R.M. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 2012, 33:579-589.
8. Pierson E., Simmons S.B., Castelli L., Goverman J.M. Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol. Rev. 2012, 248:205-215.
9. Dittel B.N. Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor. Br. J. Pharmacol. 2008, 153:271-276.
10. Maresz K., Pryce G., Ponomarev E.D., Marsicano G., Croxford J.L., Shriver L.P., et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 2007, 13:492-497.
11. Palazuelos J., Davoust N., Julien B., Hatterer E., Aguado T., Mechoulam R., et al. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J. Biol. Chem. 2008, 283:13320-13329.
12. Pryce G., Ahmed Z., Hankey D.J., Jackson S.J., Croxford J.L., Pocock J.M., et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003, 126:2191-2202.
13. Rossi S., Furlan R., De Chiara V., Muzio L., Musella A., Motta C., et al. Cannabinoid CB1 receptors regulate neuronal TNF-alpha effects in experimental autoimmune encephalomyelitis. Brain Behav. Immun. 2011, 25:1242-1248.
14. Cencioni M.T., Chiurchiu V., Catanzaro G., Borsellino G., Bernardi G., Battistini L., et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 2010, 5:e8688.
15. Zhang M., Martin B.R., Adler M.W., Razdan R.J., Kong W., Ganea D., et al. Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J. Neuroimmune Pharmacol. 2009, 4:249-259.
16. Downer E.J. Cannabinoids and innate immunity: taking a toll on neuroinflammation. Sci. World J. 2011, 11:855-865.
17. Baxter A.G. The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 2007, 7:904-912.
18. Lou Z.Y., Chen C., He Q., Zhao C.B., Xiao B.G. Targeting CB(2) receptor as a neuroinflammatory modulator in experimental autoimmune encephalomyelitis. Mol. Immunol. 2011, 49:453-461.
19. Lourbopoulos A., Grigoriadis N., Lagoudaki R., Touloumi O., Polyzoidou E., Mavromatis I., et al. Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res. 2011, 1390:126-141.
20. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 1995, 232:54-61.
21. Lee S.F., Newton C., Widen R., Friedman H., Klein T.W. Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. Eur. J. Pharmacol. 2001, 423:235-241.
22. Correa F., Mestre L., Docagne F., Guaza C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br. J. Pharmacol. 2005, 145:441-448.
23. Do Y., McKallip R.J., Nagarkatti M., Nagarkatti P.S. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J. Immunol. 2004, 173:2373-2382.
24. McCoy K.L., Matveyeva M., Carlisle S.J., Cabral G.A. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J. Pharmacol. Exp. Ther. 1999, 289:1620-1625.
25. Zhu W., Friedman H., Klein T.W. Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1. J. Pharmacol. Exp. Ther. 1998, 286:1103-1109.
26. Bidinger B., Torres R., Rossetti R.G., Brown L., Beltre R., Burstein S., et al. Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin. Immunol. 2003, 108:95-102.
27. Lombard C., Nagarkatti M., Nagarkatti P. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin. Immunol. 2007, 122:259-270.
28. Rieder S.A., Chauhan A., Singh U., Nagarkatti M., Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 2010, 215:598-605.
29. Lu T., Newton C., Perkins I., Friedman H., Klein T.W. Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J. Pharmacol. Exp. Ther. 2006, 319:269-276.
30. Newton C.A., Chou P.J., Perkins I., Klein T.W. CB(1) and CB(2) cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection. J. Neuroimmune Pharmacol. 2009, 4:92-102.
31. Yuan M., Kiertscher S.M., Cheng Q., Zoumalan R., Tashkin D.P., Roth M.D. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol. 2002, 133:124-131.
32. Hegde V.L., Hegde S., Cravatt B.F., Hofseth L.J., Nagarkatti M., Nagarkatti P.S. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol. Pharmacol. 2008, 74:20-33.
33. Gorantla S., Makarov E., Roy D., Finke-Dwyer J., Murrin L.C., Gendelman H.E., et al. Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS. J. Neuroimmune Pharmacol. 2010, 5:456-468.
34. Tschop J., Kasten K.R., Nogueiras R., Goetzman H.S., Cave C.M., England L.G., et al. The cannabinoid receptor 2 is critical for the host response to sepsis. J. Immunol. 2009, 183:499-505.
35. Wang Z.Y., Wang P., Bjorling D.E. Activation of cannabinoid receptor 2 inhibits experimental cystitis. Am J. Physiol. Regul. Integr. Comp. Physiol. 2013, 304:R846-R853.
36. Kozela E., Juknat A., Kaushansky N., Rimmerman N., Ben-Nun A., Vogel Z. Cannabinoids Decrease the Th17 Inflammatory Autoimmune Phenotype. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune. Pharmacology 2013, Paper is still on line. 10.1007/s11481-013-9493-1.
37. Chen G., Shannon M. Transcription factors and th17 cell development in experimental autoimmune encephalomyelitis. Crit. Rev. Immunol. 2013, 33:165-182.
38. McGeachy M.J., Chen Y., Tato C.M., Laurence A., Joyce-Shaikh B., Blumenschein W.M., et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol. 2009, 10:314-324.
39. Peters A., Pitcher L.A., Sullivan J.M., Mitsdoerffer M., Acton S.E., Franz B., et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011, 35:986-996.
40. Siffrin V., Radbruch H., Glumm R., Niesner R., Paterka M., Herz J., et al. In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 2010, 33:424-436.
41. Stromnes I.M., Cerretti L.M., Liggitt D., Harris R.A., Goverman J.M. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat. Med. 2008, 14:337-342.
42. Zarruk J.G., Fernandez-Lopez D., Garcia-Yebenes I., Garcia-Gutierrez M.S., Vivancos J., Nombela F., et al. Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection. Stroke 2012, 43:211-219.
43. Haines C.J., Chen Y., Blumenschein W.M., Jain R., Chang C., Joyce-Shaikh B., et al. Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23. Cell Rep. 2013, 3:1378-1388.
44. Ghosh S., Preet A., Groopman J.E., Ganju R.K. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol. Immunol. 2006, 43:2169-2179.
45. Ni X., Geller E.B., Eppihimer M.J., Eisenstein T.K., Adler M.W., Tuma R.F. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult. Scler. 2004, 10:158-164.
46. Xu H., Cheng C.L., Chen M., Manivannan A., Cabay L., Pertwee R.G., et al. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J. Leukoc. Biol. 2007, 82:532-541.
47. Adhikary S., Kocieda V.P., Yen J.H., Tuma R.F., Ganea D. Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood 2012, 120:3741-3749.
48. Singh U.P., Singh N.P., Singh B., Price R.L., Nagarkatti M., Nagarkatti P.S. Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol. Appl. Pharmacol. 2012, 258:256-267.